Active	Status	Sponsor type	Region	Phase	Filter
12 Active 3 Inactive 15 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

12 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Lindnér, Per
INTERCEPT, NCT04561986: TocIlizumab in Chronic Antibody-mediated Rejection in Kidney Transplant Recipients	Recruiting	3	50	Europe	Tocilizumab, RoActemra	Vastra Gotaland Region, Karolinska University Hospital, Uppsala University Hospital, Skane University Hospital, The Swedish Research Council	Antibody-mediated Rejection
Felldin, Marie
INTERCEPT, NCT04561986: TocIlizumab in Chronic Antibody-mediated Rejection in Kidney Transplant Recipients	Recruiting	3	50	Europe	Tocilizumab, RoActemra	Vastra Gotaland Region, Karolinska University Hospital, Uppsala University Hospital, Skane University Hospital, The Swedish Research Council	Antibody-mediated Rejection
NCT04311632: A Dose Escalation Study in de Novo Renal Transplantation	Completed	2	13	US	TCD601, Tacrolimus (TAC), Corticosteroids (CS), Mycophenolate Mofetil (MMF), ATG	ITB-Med LLC	Kidney Transplantation	10/23	10/23
Baid-Agrawal, Seema
INTERCEPT, NCT04561986: TocIlizumab in Chronic Antibody-mediated Rejection in Kidney Transplant Recipients	Recruiting	3	50	Europe	Tocilizumab, RoActemra	Vastra Gotaland Region, Karolinska University Hospital, Uppsala University Hospital, Skane University Hospital, The Swedish Research Council	Antibody-mediated Rejection
Ekberg, Jana
INTERCEPT, NCT04561986: TocIlizumab in Chronic Antibody-mediated Rejection in Kidney Transplant Recipients	Recruiting	3	50	Europe	Tocilizumab, RoActemra	Vastra Gotaland Region, Karolinska University Hospital, Uppsala University Hospital, Skane University Hospital, The Swedish Research Council	Antibody-mediated Rejection
Mjornstedt, Lars
INTERCEPT, NCT04561986: TocIlizumab in Chronic Antibody-mediated Rejection in Kidney Transplant Recipients	Recruiting	3	50	Europe	Tocilizumab, RoActemra	Vastra Gotaland Region, Karolinska University Hospital, Uppsala University Hospital, Skane University Hospital, The Swedish Research Council	Antibody-mediated Rejection
Streichart, Lillian
INTERCEPT, NCT04561986: TocIlizumab in Chronic Antibody-mediated Rejection in Kidney Transplant Recipients	Recruiting	3	50	Europe	Tocilizumab, RoActemra	Vastra Gotaland Region, Karolinska University Hospital, Uppsala University Hospital, Skane University Hospital, The Swedish Research Council	Antibody-mediated Rejection
Lennerling, Annette
INTERCEPT, NCT04561986: TocIlizumab in Chronic Antibody-mediated Rejection in Kidney Transplant Recipients	Recruiting	3	50	Europe	Tocilizumab, RoActemra	Vastra Gotaland Region, Karolinska University Hospital, Uppsala University Hospital, Skane University Hospital, The Swedish Research Council	Antibody-mediated Rejection
Bröcker, Verena
INTERCEPT, NCT04561986: TocIlizumab in Chronic Antibody-mediated Rejection in Kidney Transplant Recipients	Recruiting	3	50	Europe	Tocilizumab, RoActemra	Vastra Gotaland Region, Karolinska University Hospital, Uppsala University Hospital, Skane University Hospital, The Swedish Research Council	Antibody-mediated Rejection
Mölne, Johan
INTERCEPT, NCT04561986: TocIlizumab in Chronic Antibody-mediated Rejection in Kidney Transplant Recipients	Recruiting	3	50	Europe	Tocilizumab, RoActemra	Vastra Gotaland Region, Karolinska University Hospital, Uppsala University Hospital, Skane University Hospital, The Swedish Research Council	Antibody-mediated Rejection
Holgersson, Jan
INTERCEPT, NCT04561986: TocIlizumab in Chronic Antibody-mediated Rejection in Kidney Transplant Recipients	Recruiting	3	50	Europe	Tocilizumab, RoActemra	Vastra Gotaland Region, Karolinska University Hospital, Uppsala University Hospital, Skane University Hospital, The Swedish Research Council	Antibody-mediated Rejection
Nyström, Jenny
INTERCEPT, NCT04561986: TocIlizumab in Chronic Antibody-mediated Rejection in Kidney Transplant Recipients	Recruiting	3	50	Europe	Tocilizumab, RoActemra	Vastra Gotaland Region, Karolinska University Hospital, Uppsala University Hospital, Skane University Hospital, The Swedish Research Council	Antibody-mediated Rejection